Spirulina is one of the most popular green powders in the supplement aisle, and a new meta-analysis gives it a real, statistically significant win on one of the best-known inflammation markers in medicine. The same paper also contains a reality check that most headlines will skip. Here is what the research found, what it didn't, and who might reasonably care.
The Headline Finding: Spirulina Moved CRP
Researchers pooled data from randomized clinical trials of spirulina supplementation in adults aged 18 and older. The review was published in the International Journal for Vitamin and Nutrition Research in 2026. The team searched the Cochrane Library, ClinicalTrials.gov, ISI Web of Science, Scopus and PubMed through August 2025. Eight studies met the inclusion criteria.
Pooled across those trials, spirulina significantly reduced serum C-reactive protein (CRP) compared with placebo:
- Weighted mean difference: -0.09 mg/L
- 95% confidence interval: -0.16 to -0.02
Because the confidence interval does not cross zero, the result is statistically significant. CRP is a widely used blood marker of systemic inflammation, which is why this finding is getting attention in the "inflammaging" conversation. That term refers to the low-grade, chronic inflammation thought to rise with age and contribute to age-related disease.
The Catch: The Drop Is Small
A reduction of 0.09 mg/L is modest. The confidence interval runs from a very small drop (0.02 mg/L) to a slightly larger one (0.16 mg/L). The abstract does not say whether the change is clinically meaningful, and it makes no claims about disease outcomes. This is a lab-marker result, not evidence that spirulina slows aging, prevents heart disease or extends lifespan.
The authors' own conclusion is cautious. They call for further high-quality RCTs to confirm the benefit.
What Didn't Reach Significance: TNF-α and IL-6
The review also looked at two other inflammatory mediators. Neither showed a statistically significant change:
| Marker | Weighted mean difference | 95% CI |
|---|---|---|
| TNF-α | -0.43 pg/mL | -1.44 to 0.59 |
| IL-6 | -0.44 pg/mL | -0.98 to 0.1 |
Both intervals include zero, so the data cannot rule out no effect. The IL-6 interval only barely crosses zero, which is suggestive but not conclusive. The honest summary is that spirulina has a significant CRP signal and no confirmed effect on these two cytokines.
Doses and Durations Used in the Trials
The abstract reports the following ranges across the eight trials:
- Dose: 1 g/day to 8 g/day
- Duration: 3 to 16 weeks
That is a wide spread. The abstract does not break results down by dose or duration, so it does not tell us the best dose or whether higher doses work better. It also does not address time of day, whether to take spirulina with food, or which formulation is best. Anyone who gives a precise protocol based on this paper is going beyond the data. The most defensible takeaway is that the trials tested daily intakes in the 1 to 8 g range, over weeks to a few months.
Who Might This Be Relevant For?
The review covered adults aged 18 and older, and the abstract does not single out any specific health condition or subgroup. So this should not be read as a recommendation for any one group. Some general points follow.
- Adults interested in dietary approaches to inflammation may find the CRP result a reasonable reason to discuss spirulina with a clinician, as one low-risk option among many lifestyle strategies. The abstract does not assess safety or side effects, so "low-risk" is an assumption, not a finding.
- People with elevated CRP or an inflammatory condition should not treat spirulina as a replacement for medical care. The review did not test it that way.
- People on medication or with medical conditions should check with a healthcare professional before starting any new supplement.
Why You Should Treat the Result With Caution
The most important caveat is in the abstract itself: heterogeneity was significant for all the inflammatory mediators analyzed. In plain terms, the trials disagreed with one another more than chance would explain. That could reflect differences in dose, duration, participant health, spirulina product quality or study design. The authors used a random-effects model (DerSimonian and Laird), which accounts for some of this variability, but it does not fix it.
Other limits are worth keeping in mind:
- Small evidence base. Eight trials is not a large pool, and the abstract doesn't give participant numbers or a risk-of-bias assessment.
- Marker, not outcome. Lower CRP does not automatically translate into better health outcomes.
- Mixed results across markers. Only CRP reached significance.
- No head-to-head dosing data in the abstract to guide how much to take.
The review was registered in PROSPERO (CRD42024606496), which is a plus for transparency.
The Bottom Line
Spirulina earns a cautious thumbs-up for CRP. The meta-analysis found a statistically significant but small reduction (-0.09 mg/L) versus placebo, using doses of 1 to 8 g/day for 3 to 16 weeks. It did not find significant effects on TNF-α or IL-6, and the heterogeneity across trials was significant. As a result, spirulina is best viewed as a promising, unproven add-on for inflammation rather than an anti-aging fix. Bigger, better-controlled trials will show whether this small signal holds up.